Back

Watch Compare

Kairos Pharma, LTD.

Data quality: 83%

KAPA

NYSE Manufacturing Chemicals

$0.60

▲ $0.02 (2.56%)

6 months return

—

Momentum

Neutral

ROE

-79.75%

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-79.75%

Below sector avg (-54.49%)

ROIC-64.44%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio16.56

Interest Coverage-159.20

Valuation

PE (TTM|NTM)

-2.17 | -1.07

Below sector avg (-1.50)

P/B Ratio1.54

EV/EBITDAN/A

Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -3.44 M

Price History

Financial Trends

Analyst Price Target

3 analysts

Buy

+1288.9%

upside to target

Current

$0.60

Consensus Target

$8.33

$4.00

Low

$12.00

High

Forecast

Forward P/E

-1.07

Forward EPS

-$0.55

Est. Revenue

0.0

Earnings Surprises

EPS

Reported Estimate Forecast

Next: Q1 2026 · EPS Est: -$0.07 · Rev Est: 0.0

	Q12025	Q22025	Q32025	Q42025	Q1 '26	Q2 '26
Reported	-$0.08	-$0.08	-$0.07	-$0.07	—	—
Estimate	-$0.05	-$0.05	-$0.08	$0.03	-$0.07	-$0.08
Surprise	-60.00%	-60.00%	+6.67%	-333.33%	—	—

Growth

Rev 5Y: N/A · Earnings 1Y: N/A

Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A

Profitability

ROE: -79.75% · Net Margin: N/A

Revenue (TTM)	N/A	Net Income (TTM)	-5.45 M
ROE	-79.75%	ROA	-73.91%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-3.44 M
ROIC	-64.44%	FCF Growth (3Y)	N/A

Safety

D/E: N/A · Current: 16.56

Debt / Equity	N/A	Current Ratio	16.56
Interest Coverage	-159.20	Asset Turnover	N/A
Working Capital	6.25 M	Tangible Book Value	7.56 M

Dividends

Yield: N/A · Payout: N/A

Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A

Valuation

P/E: -2.17 · EV/EBITDA: N/A

P/E Ratio	-2.17	Forward P/E	-1.07
P/B Ratio	1.54	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-29.10%
Market Cap	11.83 M	Enterprise Value	6.25 M

Per Share

EPS: -0.30 · FCF/Share: -0.16

EPS (Diluted TTM)	-0.30	Revenue / Share	N/A
FCF / Share	-0.16	OCF / Share	-0.16
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A

Efficiency

FCF Conv: 63.17% · CapEx/Rev: N/A

CapEx / Revenue	N/A	FCF Conversion	63.17%
SBC-Adj. FCF	N/A	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024
Revenue	—	—
Net Income	-5.45 M	-2.60 M
EPS (Diluted)	-0.30	-0.23
Gross Profit	—	—
Operating Income	-5.57 M	-2.34 M
EBITDA	—	—
R&D Expenses	2.14 M	414,000.0
SG&A Expenses	—	—
D&A	—	—
Interest Expense	35,000.0	35,000.0
Income Tax	—	—

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024
Total Assets	6.54 M	5.77 M
Total Liabilities	—	992,000.0
Shareholders' Equity	6.34 M	4.78 M
Total Debt	—	—
Cash & Equivalents	4.49 M	—
Current Assets	5.39 M	4.17 M
Current Liabilities	199,000.0	992,000.0

Peer Comparison

vs Manufacturing sector median (1605 peers)

Metric	Stock	Sector Median
P/E	-2.2	-1.5
P/B	1.5	1.6
ROE %	-79.8	-54.5
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	—	0.3